Patents by Inventor José Alain Sahel

José Alain Sahel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210085172
    Abstract: A method of analyzing a visual field of an individual comprises the following steps:—measuring (S4) a first visual field (VF1) of said individual for a first set of oculo-postural parameters of said individual when said individual performs a first task;—measuring (S6) at least one additional visual field (VFi) of said individual for one additional set of said oculo-postural parameters of said individual when said individual performs an additional task;—determining (S8) a functional visual space based on said first visual field (VF1) and said at least one additional visual field (VFi), said functional visual space being an envelope of said first visual field and said at least one additional visual field. The additional task differs from said first task and/or said additional set of oculo-postural parameters differs from said first set of oculo-postural parameters. A corresponding ophthalmic lens is also proposed.
    Type: Application
    Filed: December 21, 2017
    Publication date: March 25, 2021
    Inventors: José-Alain SAHEL, Angelo ARLEO, Anne-Catherine SCHERLEN, Delphine TRANVOUEZ-BERNARDIN
  • Patent number: 10955654
    Abstract: Disclosed is an imaging device including a light source arranged so as to generate an optical signal, an optical support coupled to the light source and arranged so as to project a luminous excitation signal with a substantially constant light intensity, from the light source to a body to be observed during the use of the device, and an asynchronous camera coupled to the optical support and designed so as to generate a signal including, for each pixel of a first pixel matrix, a signal sequence representing asynchronous events corresponding to variations of the light backscattered by the body to be observed for the pixel.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: March 23, 2021
    Assignees: SORBONNE UNIVERSITÉ, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PARIS-SUD, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS—APHP
    Inventors: Guillaume Chenegros, Ryad Benosman, Nicolas Libert, Jacques Durenteau, Anatole Harrois, Serge Picaud, Jose-Alain Sahel
  • Publication number: 20210069346
    Abstract: The invention relates to the use of HNRNPC-expressing vectors for preventing and/or treating a tauopathy, such as Alzheimer's disease. The invention relates to methods for detecting a risk of developing a tauopathy such Alzheimer's disease in a patient, comprising the step of detecting the level of HNRNPC in a biological sample obtained from said patient.
    Type: Application
    Filed: November 6, 2020
    Publication date: March 11, 2021
    Inventors: Thierry Leveillard, Jose-Alain Sahel, Hawa Camara
  • Publication number: 20210002607
    Abstract: The disclosure pertains to a defined cell culture medium for the expansion of human retinal progenitors, comprising or consisting of a nutrient medium, a SHH-pathway activator and a GSK3 inhibitor. To the use of the defined cell culture medium for the expansion of retinal progenitors, as well as to an in vitro method for expanding retinal progenitors, comprising: (i) placing a culture of human retinal progenitors in a defined cell culture medium as defined in claims 1 to 8; and (ii) culturing the cells in said defined cell culture medium.
    Type: Application
    Filed: March 6, 2019
    Publication date: January 7, 2021
    Applicants: SORBONNE UNIVERSITE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Sacha Reichman, Olivier Goureau, José-Alain Sahel
  • Patent number: 10857239
    Abstract: The invention relates to the use of HNRNPC-expressing vectors for preventing and/or treating a tauopathy, such as Alzheimer's disease. The invention relates to methods for detecting a risk of developing a tauopathy such Alzheimer's disease in a patient, comprising the step of detecting the level of HNRNPC in a biological sample obtained from said patient.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: December 8, 2020
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS, UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6)
    Inventors: Thierry Leveillard, Jose-Alain Sahel, Hawa Camara
  • Publication number: 20200318138
    Abstract: The present invention relates to improved constructs comprising the short and long Rod-Derived Cone Viability Factors and to methods for treating retinal degenerative diseases.
    Type: Application
    Filed: December 21, 2018
    Publication date: October 8, 2020
    Inventors: Thierry LEVEILLARD, Najate AÏT-ALI MAAMRI, Fréderic BLOND, José-Alain SAHEL, Géraldine PUEL, Emmanuelle CLERIN
  • Publication number: 20200277623
    Abstract: An expression vector containing appropriate mitochondrion-targeting sequences (MTS) and appropriate 3?UTR sequences provides efficient and stable delivery of a mRNA encoding a protein (CDS) to the mitochondrion of a mammalian cell. The MTS and 3?UTR sequences guide the CDS mRNA from the nuclear compartment of the cell to mitochondrion-bound polysomes, where the CDS is translated. This provides an efficient translocation of a mature functional protein into the mitochondria. A method of targeting mRNA expressed in the nuclear compartment of a mammalian cell to the mitochondrion is also provided. The vector and methods can be used to treat defects in mitochondrial function.
    Type: Application
    Filed: September 18, 2019
    Publication date: September 3, 2020
    Inventors: Marisol CORRAL-DEBRINSKI, Jose-Alain SAHEL, Valerie KALTIMBACHER, Crystel BONNET
  • Publication number: 20200174023
    Abstract: The present invention concerns a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound selected in the group comprising (i) a polypeptide comprising an amino acid sequence selected in the group comprising the amino acid sequence of the long isoform in Homo sapiens of the RdCVF2 gene (SEQ ID NO: 10), orthologs, derivatives and fragments thereof, (ii) a polynucleotide coding for said polypeptide, (iii) a vector comprising said polynucleotide, and (iv) a host cell genetically engineered expressing said polypeptide; the use of such a composition for the manufacture of a medicament for treating and/or preventing a neurodegenerative disorder in a subject; and a method of testing a subject thought to have or be predisposed to having a neurodegenerative disorder.
    Type: Application
    Filed: December 12, 2019
    Publication date: June 4, 2020
    Inventors: Thierry Leveillard, Jose-Alain Sahel, Celine Jaillard, Olivier Poch
  • Patent number: 10668129
    Abstract: The present invention relates to the synergistic combination of the short and long Rod-Derived Cone Viability Factors and to methods for treating retinal degenerative diseases.
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: June 2, 2020
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS, UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6), THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Thierry Leveillard, John Flannery, Xin Mei, Leah Byrne, José-Alain Sahel, Emmanuelle Clerin-Lachapelle, Junwei Sun, Jean Bennett, Jeannette Bennicelli
  • Patent number: 10559247
    Abstract: A method of controlling the display of images in the form of a pixel array, includes for a pixel of the array, asynchronous information representing events concerning the pixel is received, a first activation of the pixel is actuated at an activation time determined by a first event of the asynchronous information, and at least a second activation of the pixel is actuated in order to repeat the first activation of the pixel at respective times defined by a refresh sequence.
    Type: Grant
    Filed: March 18, 2015
    Date of Patent: February 11, 2020
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS, SORBONNE UNIVERSITE
    Inventors: Ryad Benosman, Guillaume Chenegros, Sihem Kime, Siohoi Ieng, Jose-Alain Sahel
  • Publication number: 20200032203
    Abstract: The present invention relates to photoreceptor precursor cells comprising a heterologous nucleic acid encoding an optogenetic inhibitor. The present invention also relates to a pharmaceutical composition comprising photoreceptor precursor cells of the invention and a pharmaceutically acceptable excipient. The present invention relates to photoreceptor precursor cells or pharmaceutical composition of the invention for use in the treatment of a retinal degenerative disease, preferably a retinal degenerative disease related to a loss of function or death of photoreceptors. Finally, the present invention relates to a method for producing the photoreceptor precursor cells of the invention, comprising i) providing photoreceptor precursor cells; and ii) introducing into said precursor cells a nucleic acid encoding optogenetic inhibitor.
    Type: Application
    Filed: September 22, 2017
    Publication date: January 30, 2020
    Inventors: JENS DUEBEL, MARIUS ADER, ANTOINE CHAFFIOL, MARCELA GARITA-HERNANDEZ, MARUSA LAMPIC, DENIZ DALKARA, OLIVIER GOUREAU, JOSÉ-ALAIN SAHEL
  • Patent number: 10519232
    Abstract: The present invention relates to preventive and/or therapeutic agents for use in the treatment of retinal inflammation, and more specifically of Age-related macular degeneration and Retinitis pigmentosa, wherein said agents are selected from an IL-6 inhibitor, an APOE inhibitor and/or a Fas activator as an active ingredient.
    Type: Grant
    Filed: January 22, 2015
    Date of Patent: December 31, 2019
    Assignees: SORBONNE UNIVERSITE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Florian Sennlaub, Xavier Guillonneau, Olivier Levy, José-Alain Sahel
  • Patent number: 10513503
    Abstract: Disclosed is a method for the treatment, prevention and/or stabilisation of ARMD, Stargardt disease, pigmentary retinopathy and/or diabetic retinopathy, including the application of a 3-deoxyanthocyanidin of formula (I) in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and X? are as defined, with the condition that at least one of R1, R2, R3, R4 or R5 is a hydroxyl and at least one of R8, R9, R10 or R11 is a hydroxyl.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: December 24, 2019
    Assignees: BIOPHYTIS, SORBONNE UNIVERSITE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE
    Inventors: Valerie Fontaine, Rene Lafont, Jose-Alain Sahel, Stanislas Veillet
  • Publication number: 20190370542
    Abstract: Disclosed is a method for pattern recognition in a plurality of received time signals of different types, the method includes: b) for each received signal, creating an asynchronous time signal including events; c) for each created asynchronous signal, creating an activity profile of the asynchronous signal which decreases as a function of the time elapsed since the last event of the asynchronous signal; d) for a given time t0: d1) determining a context defined as the set of activity profiles of the created asynchronous signals, d2) determining a standard context among predetermined standard contexts, having a minimum distance to the context determined in step d1, d3) determining the pattern as a function of the determined standard context.
    Type: Application
    Filed: September 8, 2017
    Publication date: December 5, 2019
    Inventors: Kevin GEHERE, Germain HAESSIG, Ryad BENOSMAN, Sio Hoi IENG, José-Alain SAHEL, Guillaume CHENEGROS, Nicolas LIBERT
  • Publication number: 20190298797
    Abstract: The present invention relates to lebecetin, a functional variant or fragment thereof, for use as neovascularization inhibitor, in particular in the treatment of neovascular diseases such as ocular diseases, cancers or inflammatory disorders with a neovascular component.
    Type: Application
    Filed: December 12, 2017
    Publication date: October 3, 2019
    Inventors: XAVIER GUILLONNEAU, FADOUA MONTASSAR, NAZIHA MARRAKCHI, ERIJ MESSADI, FLORIAN SENNLAUB, JOSÉ-ALAIN SAHEL
  • Publication number: 20190225649
    Abstract: Disclosed are agents activating CD47 and their use in the treatment of inflammation, in particular non-resolving low grade inflammation, characterized by chronic MP infiltration, such as age-related macular degeneration. Also disclosed are pharmaceutical compositions, medicaments and kits including the agents.
    Type: Application
    Filed: May 10, 2017
    Publication date: July 25, 2019
    Inventors: Florian SENNLAUB, Michael HOUSSET, Xavier GUILLONNEAU, José-Alain SAHEL, Philippe KAROYAN
  • Patent number: 10314804
    Abstract: A method of photoprotecting cells of the retinal pigment epithelium (EPR) in mammals using a composition having norbixin. The norbixin is produced by purification from an extract of Bixa orellana seeds.
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: June 11, 2019
    Assignees: BIOPHYTIS, SORBONNE UNVERSITÉ
    Inventors: René Lafont, Stanislas Veillet, José-Alain Sahel, Valérie Fontaine, Pierre-Paul Elena
  • Publication number: 20190064189
    Abstract: The present invention concerns a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound selected in the group comprising (i) a polypeptide comprising an amino acid sequence selected in the group comprising the amino acid sequence of the long isoform in Homo sapiens of the RdCVF2 gene (SEQ ID NO: 10), orthologs, derivatives and fragments thereof, (ii) a polynucleotide coding for said polypeptide, (iii) a vector comprising said polynucleotide, and (iv) a host cell genetically engineered expressing said polypeptide; the use of such a composition for the manufacture of a medicament for treating and/or preventing a neurodegenerative disorder in a subject; and a method of testing a subject thought to have or be predisposed to having a neurodegenerative disorder.
    Type: Application
    Filed: October 2, 2018
    Publication date: February 28, 2019
    Inventors: Thierry Leveillard, Jose-Alain Sahel, Celine Jaillard, Olivier Poch
  • Publication number: 20190010235
    Abstract: Disclosed are agents inhibiting the interaction between CFH and CD11b/18, as well as the use of such agents, in particular for treating inflammatory disorders, such as age-related macular degeneration.
    Type: Application
    Filed: December 23, 2016
    Publication date: January 10, 2019
    Inventors: Florian SENNLAUB, Bertrand CALLIPPE, Xavier GUILLONNEAU, José-Alain SAHEL
  • Publication number: 20180353482
    Abstract: Disclosed is a method utilizing (R)-2-(2-aminothiazol-4-yl)-4?-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide or an analogue, pharmaceutically acceptable salt or solvate thereof for the treatment of a retinal disease, more specifically using mirabegron for the treatment of age-related macular degeneration. Also Disclosed is a pharmaceutical composition, a medicament and a kit for the treatment of age-related macular degeneration.
    Type: Application
    Filed: November 17, 2016
    Publication date: December 13, 2018
    Inventors: Valérie FONTAINE, Cécile VIDAL, José-Alain SAHEL